

CDC Foundation Active Programs
October 1, 2024 - September 30, 2025

This document provides a list of CDC-led CDC Foundation programs that were active between October 1, 2024, and September 30, 2025. Each program listing includes program name, description, funding partner(s), dates for the programs and amounts of the funding provided during the fiscal year. Where applicable, funding partners from previous years are listed. Note that the dates used for active projects match CDC's fiscal year and not the CDC Foundation's fiscal year, which runs July 1 through June 30.



(The CDC Foundation has updated this report to reflect the report's purpose of providing transparent data on external funders contributing to CDC-led and/or CDC-initiated programs. For a listing of the CDC Foundation's donors and gifts partner information, please see the CDC Foundation's Report to Congress linked from our website.)

					CDC Fiscal Year 2025		
Start Date	End Date	Program Name	Program Description	Funding Partner (* Indicates a funding partner in CDC fiscal year)	Committed Award	Cash	Cumulative Funding (All Years)
9/20/2024	On-going	A Day at CDC for Veterinary Students	To enable veterinary students from across the United States, Canada and the Caribbean to learn more about opportunities in public health for veterinary professionals.				\$41,007.35
				American Veterinary Medical Foundation*	\$10,000.00		
				Boehringer Ingelheim USA Corporation*	\$24,000.00		
				National Pork Board*	\$6,000.00		
				Various Individual Contributors*	\$1,007.35		
9/1/2015	1/13/2025	AIDS and Kaposi's Sarcoma in Uganda	To perform Human Herpesvirus-8 (HHV-8) diagnostics on specimens from a University of California San Francisco study on antiretroviral therapy for patients with AIDS and Kaposi's sarcoma in Uganda.				\$63,000.00
				University of California, San Francisco			
10/1/2020	9/30/2026	Analysis of Immunogenicity and Shedding of New Oral Poliovirus Vaccines	To provide laboratory support for the analysis of immunogenicity and shedding of new oral Poliovirus vaccines in human clinical trials and related issues for polio endgame.				\$8,469,798.00
				Gates Foundation			
12/20/2024	6/30/2026	Antibiotic Stewardship Resources	To improve use of antibiotics in outpatient settings, where most prescribing occurs, by providing antibiotic stewardship resources for state health departments and state Medicaid agencies.				\$200,000.00
				The Pew Charitable Trusts*	\$200,000.00		
11/7/2024	10/31/2026	Antimalarial Resistance Monitoring in Africa Pt. II	To continue to develop and validate nanopore amplicon sequencing assay (NOMADS) to accelerate antimalarial resistance surveillance in Africa.				\$1,453,593.00
				Gates Foundation*	\$1,453,593.00		
9/20/2019	3/31/2027	Biomarker Discovery through Serum Epitope Repertoire Analysis (SERA)	To optimize interventions and tools to enable the elimination and eradication of prioritized Neglected Tropical Diseases (NTDs) as identified by the London Declaration.				\$4,792,434.00
				Gates Foundation			
11/15/2024	5/14/2027	Building National and State Surveillance for Key Nutrition Topics for all Children	To add three nutrition questions on the National Survey of Children's Health (NSCH) for the next available survey cycle (2025 or 2026) to be asked of all children aged 1-17 years. This will yield nationally representative and state-level estimates of key dietary behaviors for all children aged 1-17 years.				\$500,000.00
				Robert Wood Johnson Foundation*	\$500,000.00		
10/20/2021	3/31/2025	Characterization of Non-Rotavirus Viral Diarrheal Pathogens	To support the characterization of non-rotavirus viral diarrheal pathogens to inform the body of work that contributes to optimizing the efficacy of rotavirus vaccines.				\$1,211,158.00
				Gates Foundation			
7/17/2015	12/6/2024	Chronic Hepatitis B Virus Infection in Tanzania	To implement and evaluate the feasibility of a care and treatment model for persons infected with chronic hepatitis B virus in resource-limited settings.				\$439,252.74

Start Date	End Date	Program Name	Program Description	Funding Partner (* Indicates a funding partner in CDC fiscal year)	Committed Award	Cash	Cumulative Funding (All Years)
				Gilead Sciences, Inc.			
11/9/2024	5/31/2026	Controlled Human Infection Model (CHIM) Study	To identify the best rotavirus challenge strain for Controlled Human Infection Model (CHIM) study.				\$745,696.00
				Gates Foundation*	\$745,696.00		
6/1/2020	12/31/2025	Controlling Mosquito Vectors of Malaria	To develop data that will contribute to an assessment of whether transgenic mosquitoes could be effectively and safely deployed to control natural populations of malaria vectors.				\$4,359,806.36
				Imperial College London*	\$1,064,181.20		
7/21/2023	3/1/2026	Cryopreservation and artificial insemination for Anopheles mosquitoes	To continue project in cryopreservation and suppression of female development in mosquitoes to assist research for malaria control.				\$900,000.00
				Good Ventures Foundation			
3/1/2015	3/31/2025	Data for Health	To assist 25 low- and middle-income countries across Latin America, Asia and Africa in strengthening their public health data systems and data use for critical policy-making decisions.				\$64,586,222.15
				Bloomberg Philanthropies			
8/1/2024	6/30/2027	Data for Health Supplemental Project	To collect birth and death data through surveys in focus countries to help improve data use by government agencies and public health professionals.				\$2,285,000.00
				Bloomberg Philanthropies*	\$1,700,000.00		
4/1/2023	3/31/2027	Data for Health, Phase 5	To provide a collection of birth and death data through surveys in focus countries to help improve data use by government agencies and public health professionals.				\$33,430,000.00
				Bloomberg Philanthropies*	\$16,730,000.00		
6/28/2024	On-going	Development and Dissemination of Findings and Methodology on Inclusive Education	To develop questions on out-of-school children for the UNICEF Multiple Indicators Cluster Surveys and share the methodological insights from the study at conferences and workshops.				\$23,680.80
				The Center for Inclusive Policy (CIP)			
8/13/2024	2/28/2026	Development of a Microarray Patch for Delivery of Long-Acting Antivirals	To provide project management services to include management of design and performance by CDC involving application of microarray patches (MAPs) containing antiretrovirals for HIV treatment.				\$386,823.00
				PATH			
6/13/2019	2/23/2025	Digital Bridge Information Exchange between Healthcare Sector and Public Health	To use a public-private partnership model that includes significant collaboration among three major stakeholder communities (healthcare providers, healthcare information technology vendors and public health) to promote crucial health data interoperability.				\$4,788,828.00
				Sergey Brin Family Foundation			
9/1/2019	12/31/2024	Eliminating Lymphatic Filariasis in American Samoa	To stop the spread of lymphatic filariasis and alleviate the suffering of those impacted by providing technical support to the department of health with the goal of eliminating lymphatic filariasis in American Samoa by 2025.				\$1,000,000.00
				Margaret A. Cargill Philanthropies			
11/1/2023	10/15/2025	Emerging Infections Resources Program	To maintain, produce, authenticate and distribute arthropod vectors and associated reagents for the Biological and Emerging Infections Research Resources Program (BEI-RRP).				\$1,130,673.00
				American Type Culture Collection*	\$573,691.00		
9/16/2022	9/30/2026	Evaluating Human Papillomavirus (HPV) Vaccine Induced Antibodies in Botswana	To evaluate the impact of Human Papillomavirus (HPV) vaccines and the persistence of HPV antibodies among HPV-vaccinated women living with HIV in Botswana.				\$513,703.00
				Copan Diagnostics, Inc.			
				Gates Foundation			

Start Date	End Date	Program Name	Program Description	Funding Partner (* Indicates a funding partner in CDC fiscal year)	Committed Award	Cash	Cumulative Funding (All Years)
2/22/2021	5/31/2027	Evaluating the Impact of the Pneumococcal Conjugate Vaccine Intro in Indonesia	To conduct an evaluation before and two years after the introduction of the Pneumococcal conjugate vaccines (PCV) to study the direct and indirect impact of PCV introduction on vaccine-type pneumococcal carriage among healthy Indonesian children under five years of age.				\$2,850,019.00
				Gates Foundation			
9/30/2021	9/30/2026	Evaluating Tuberculosis Preventive Treatment in People Living with HIV	To determine the impact of Tuberculosis preventative treatment among populations living with HIV.				\$4,766,680.00
				Gates Foundation			
3/28/2024	3/5/2025	Evaluation of Malaria Specimen Bank Phase VII	To conduct performance evaluations, including operational characteristics of malaria rapid diagnostic tests submitted for WHO for assessment under the WHO Prequalification of In Vitro Diagnostics submitted to WHO for assessment under the Emergency Use Listing.				\$286,655.00
				World Health Organization (WHO)			
3/20/2020	12/31/2024	Evaluation of Malaria Vaccine Implementation	To strengthen the evidence on the RTS,S/AS01 malaria vaccine: assessment of safety and effectiveness using case-control studies.				\$361,345.00
				World Health Organization (WHO)			
11/3/2018	12/31/2026	Evaluation of Pneumococcal Conjugate Vaccine Schedule Change	To evaluate the impact of a pneumococcal conjugate vaccine schedule change in Mozambique on vaccine-type pneumococcal carriage and invasive pneumococcal disease; and serotype 1 colonization among patients with suspected pneumonia and serotype 1 disease among children and adults.				\$3,712,566.00
				Gates Foundation			
5/16/2022	3/6/2025	Expanding Firefighting Personal Protective Equipment Cleaning Validation Procedures	To lessen firefighter exposure to harmful contaminants from uncleaned or improperly cleaned personal protective equipment (PPE) that improves firefighter safety and health.				\$270,841.00
				The Fire Protection Research Foundation			
4/3/2022	5/31/2025	Field Epidemiology Training Program (FETP) in Qatar	To assist the Ministry of Public Health in establishing a Field Epidemiology Training Program (FETP) in Qatar focused on building its public health workforce capacity.				\$2,311,663.00
				State of Qatar Ministry of Public Health			
11/1/2008	9/30/2026	Field Epidemiology Training Program (FETP) in Saudi Arabia - Phase II	To evaluate Saudi Arabia's infectious disease surveillance system, help train local and regional disease detectives and improve the country's capacity to monitor for and respond to infectious disease outbreaks.				\$4,880,191.08
				Kingdom of Saudi Arabia Ministry of Health			
8/28/2023	12/31/2025	Framework to Prioritize Global Tuberculosis (TB) Data	To develop a framework for countries and national tuberculosis (TB) control programs to prioritize the collection, analysis and use of supplementary TB data. Such TB data can then be used to develop better National Strategic Plans for TB towards ending TB.				\$800,520.00
				Gates Foundation			
7/1/2022	12/31/2025	GAVI Alliance Partner Engagement Framework (2022–2025)—Foundational Support	To coordinate the programmatic implementation of Gavi's 2022–2025 Partners' Engagement Framework, leading to increased equitable use of vaccines in lower-income countries.				\$1,034,000.00
				Gavi Alliance			
10/1/2022	12/31/2025	GAVI Alliance Partner Engagement Framework (2022–2025)—Strategic Focus Area	This funding will help implement the CDC Foundation programs and activities supporting the Strategic Focus Area (SFA) portion of the 2022–2025 Partners' Engagement Framework.				\$2,037,848.80
				Gavi Alliance			
10/1/2022	12/31/2025	GAVI Alliance Partner Engagement Framework (2022–2025)—Targeted Country Assistance (TCA)	To help implement the CDC Foundation programs and activities supporting the Targeted Country Assistance portion of the 2022–2025 Partners' Engagement Framework.				\$3,683,715.67
				Gavi Alliance*	\$568,960.00		

Start Date	End Date	Program Name	Program Description	Funding Partner (* Indicates a funding partner in CDC fiscal year)	Committed Award	Cash	Cumulative Funding (All Years)
6/11/2024	5/1/2027	Global Guinea Worm Eradication Program Laboratory Support	To support CDC with diagnostic development and processing for the global Guinea Worm Eradication Program. This project will provide CDC with the laboratory support needed to diagnose possible Guinea worm specimens submitted by endemic and non-endemic countries and to validate and/or develop novel Guinea worm diagnostic tests.				\$684,597.00
				The Carter Center, Inc.			
3/15/2024	6/9/2025	Global Pediatric Diarrheal Surveillance Network	To support typing of non-rotavirus enteric virus samples from World Health Organization's (WHO) global pediatric diarrheal surveillance network.				\$272,462.00
				HilleVax, Inc.*	\$168,163.00		
8/21/2019	On-going	Global Pediatric Norovirus Surveillance Network	To develop a Global Pediatric Norovirus Laboratory Surveillance Network to monitor norovirus strains and provide data critical for decision-making related to norovirus vaccination.				\$339,000.00
				Individual Contributor			
				Takeda Vaccines, Inc.			
				Vaxart, Inc.			
12/5/2023	10/5/2025	Global Pediatric Norovirus Surveillance Network Part 2	To develop expansion of Global Pediatric Norovirus Laboratory Surveillance Network to monitor norovirus strains and provide data critical for decision-making related to norovirus vaccination.				\$454,475.00
				HilleVax, Inc			
				Vaxart, Inc.			
2/1/2020	11/30/2025	Global Pneumococcal Sequencing 2.0	To generate knowledge on the globally spreading Streptococcus pneumoniae (pneumococcal) lineages that may drive serotype replacements in pneumococcal pneumonia and changes in the prevalence of antibiotic resistance in the post-PCV13 era.				\$735,104.00
				Wellcome Sanger Institute*	\$90,941.00		
12/1/2020	7/31/2025	HIV Prevention Trials Network	To evaluate the efficacy of injectable pre-exposure prophylaxis (PrEP) for HIV-uninfected populations.				\$5,574,850.00
				FHI 360			
12/1/2009	On-going	Hormone Laboratory Collaborations	To help CDC provide reference and quality control materials for laboratory collaboration, including collaborations for the Hormone Measurement Standardization program.				\$7,104,461.48
				Abbott Ireland			
				Abbott Laboratories			
				Abbott Standard Diagnostics, Inc.			
				Academic Hospital Paramaribo			
				Academisch Ziekenhuis Leiden h.o.d.n Leiden			
				University Medical Centre (LUMC)			
				Affimedix, Inc.			
				American Association for Clinical Chemistry, Inc.			
				American University of Beirut			
				Ann & Robert H. Lurie Children's Hospital of Chicago			
				Annar Diagnostica			
				ARUP Laboratories			
				Beckman Coulter			
				Bioamoy International Limited			
				Biohit Laboratory Services			
				Bio-Rad Laboratories, Inc.			
				BioReference Laboratories, Inc.			
				BMH Holdings LLC			
				Boditech Med, Inc.			
				Boston Medical Center			

Start Date	End Date	Program Name	Program Description	Funding Partner (* Indicates a funding partner in CDC fiscal year)	Committed Award	Cash	Cumulative Funding (All Years)
				Brigham and Women's Hospital			
				Calbiotech, Inc.			
				Cardiff and Vale University Health Board			
				Centre Hospitalier Universitaire of Liege			
				Centre of Reproductive Medicine and Andrology of the University			
				CEQAL			
				Cerilliant Corporation			
				Chemux Bioscience, Inc.			
				Children's Hospital Corporation dba Boston Children's Hospital			
				Chromsystems Instruments & Chemicals GMBH			
				Chungnam National University			
				Cleveland Clinic			
				Clinical Pathology Laboratories, Inc.			
				College of American Pathologists			
				College of American Pathologists Foundation			
				Copenhagen University Hospital			
				Covance Central Laboratory Services			
				Craft Technologies, Inc.			
				Diagnostic Lab for Endocrinology			
				Diagnostics Biochem Canada, Inc.			
				DiaSorin			
				DiaSource Immunoassays SA			
				Diazyme Laboratories			
				Douglass Hanly Moir Pathology			
				Endoceutics, Inc.			
				Endocrine Sciences, Inc.			
				Epitope Diagnostics, Inc.			
				Erasmus MC Rotterdam			
				Esoterix, Inc.			
				Eurofins Biomnis			
				Euroimmun Medizinische Labordiagnostika AG			
				Fujirebio Diagnostics, Inc.			
				Gangnam Severance Hospital, Yonsei University			
				Government of Canada			
				Green Cross Laboratories (GC Labs)			
				Grupo Fleury			
				Hasselt University			
				Health Canada			
				Heartland Assays, LLC			
				The Hong Kong Polytechnic University			
				IBL International			
				IDS Immunodiagnostic Systems SA			
				Imundiagnostik AG			
				Immunotech S.A.S.			
				Imperial Health Charity			
				InSource Diagnostics			
				inVentiv Health Clinical Lab, Inc.			
				Johns Hopkins University			
				Kaiser Permanente			
				Kansas City VA Medical Center			
				King Saud University			
				Konkuk University of Medicine and Medical Center			
				Laboratorios Ruiz			
				Laboratory Alliance of Central New York			
				Laboratory Corporation of America Holdings			

Start Date	End Date	Program Name	Program Description	Funding Partner (* Indicates a funding partner in CDC fiscal year)	Committed Award	Cash	Cumulative Funding (All Years)
				Los Angeles Biomedical Research Institute			
				Mayo Clinic			
				Mayo Foundation for Medical Education and Research			
				MCL A Co-Tenancy Laboratory			
				Memorial Sloan-Kettering Cancer Center			
				Microgenics Corporation			
				Micromass UK, Ltd.			
				Monobind, Inc.			
				NanoEnTek, Inc.			
				New England Research Institutes, Inc.			
				Oklahoma State University			
				Opko Diagnostics, LLC			
				Ortho-Clinical Diagnostics			
				Partners HealthCare System, Inc.			
				Pathology Associates Medical Laboratories			
				Penn State University Hershey Medical Center			
				Pennington Biomedical Research Foundation			
				Pennsylvania State University			
				PPD Development, LP			
				QLoudLab SA			
				Qualigen, Inc.			
				Quest Diagnostics Incorporated			
				Quest Diagnostics Nichols Institute Valencia			
				Quidel Corporation			
				RCPA Quality Assurance Programs Pty Limited			
				Reprosource Fertility Diagnostics			
				Roche Diagnostics Corporation			
				Sahlgrenska University Hospital			
				SCIEX			
				Seoul Medical Science Institute			
				Siemens Healthcare Diagnostics, Inc.			
				Siemens USA			
				Snibe Diagnostics (Snibe Co., Ltd.)			
				Social & Scientific Systems, Inc.			
				St. Elizabeth Healthcare			
				Syneos Health			
				Taylor Technology, Inc.			
				Theranos			
				Thermo Fisher Scientific			
				Tosoh Bioscience, Inc.			
				Tosoh Corporation			
				Tricore Reference Laboratories			
				University College Cork			
				University Hospitals Birmingham NHS Foundation Trust			
				University of Birmingham			
				University of California, San Francisco			
				University of Copenhagen			
				University of Helsinki			
				University of Hong Kong			
				University of Maryland Medical Center			
				University of Maryland, Baltimore			
				University of Massachusetts Amherst			
				University of Minnesota			
				University of Washington			
				University of Western Australia			

Start Date	End Date	Program Name	Program Description	Funding Partner (* Indicates a funding partner in CDC fiscal year)	Committed Award	Cash	Cumulative Funding (All Years)
				Virginia Commonwealth University Health System			
				VU University Medical Center Amsterdam			
				Waters Technologies Corporation			
				Waters Technologies Ireland Ltd.			
				XCellAssay, LLC			
				Zeus Scientific, Inc.			
				Zhejiang Disigns Diagnostics			
				ZRT Laboratory, LLC			
8/1/2016	On-going	Hormone Laboratory Collaborations 2.0	To help CDC provide reference and quality control materials for laboratory collaboration, including collaborations for the Hormone Measurement Standardization program.				\$435,372.57
				National Institutes of Health			
10/1/2018	12/31/2025	Immunologic Endpoints Against Young Infant Group B Streptococcal Disease	To provide a case-control study comparing naturally occurring Group B Streptococcus antibodies in young infants with invasive disease versus controls that will establish antibody thresholds associated with protection and inform decisions about future maternal Group B Streptococcus vaccine licensure.				\$4,920,068.00
				Gates Foundation			
10/14/2022	12/31/2024	Impact of CDC-Tuberculosis Preventative Treatment Studies	To enhance the informativeness and impact of the CDC-Tuberculosis Preventative Treatment studies by funding technical experts to partner in the production of updated protocols, updated statistical analysis plans and a multi-country meta-analysis.				\$202,881.00
				Gates Foundation			
10/1/2021	9/30/2026	Implementation and Monitoring of Overdose Prevention Programs and Policies	To combat the drug overdose epidemic in the United States, timely, comprehensive and high-quality data are needed to detect emerging drug use trends, ensure a nimble approach and drive evidence-based prevention and response strategies. This project will 1) build capacity among medicolegal death investigation (MDI) offices to collect and share death data and 2) identify and develop a set of overdose prevention indicators for local and state jurisdictions to track and improve efforts.				\$5,145,000.00
				Bloomberg Philanthropies			
5/5/2022	12/31/2024	Improving Water, Sanitation and Hygiene Services in Healthcare Facilities	To expand CDC's strategic engagement in learning and evaluation of best practices for water, sanitation and hygiene (WASH) in health care facilities through implementation of targeted action research pilots in Uganda.				\$200,000.00
				Wallace Genetic Foundation			
10/7/2024	4/1/2027	Inactivated Rotavirus Vaccine Clinical Material	To support the production and qualification of inactivated rotavirus vaccine clinical material.				\$3,801,869.00
				Gates Foundation*	\$3,801,869.00		
9/20/2019	8/31/2026	Indian Rotavirus Vaccines in Early Adopter Countries	To show the health impact of low-cost, Indian-made rotavirus vaccines in high burden, low-income countries of Africa and Asia.				\$1,673,274.00
				Gates Foundation			
3/1/2023	2/28/2025	Investigating the Biocompatibility of Biodegradable Subcutaneous Implant	To investigate the biocompatibility, the drug release profile and length of prophylactic efficacy of a biodegradable subcutaneous implant containing antiretroviral drug(s), developed by RTI.				\$195,656.00
				Research Triangle Institute (RTI International)			
4/1/2023	3/31/2026	Investigating Long-Acting Pre-Exposure Prophylaxis (PrEP) Formulations	To investigate long-acting pre-exposure prophylaxis (PrEP) formulations.				\$171,690.00
				University of North Carolina at Chapel Hill*	\$97,939.00		

Start Date	End Date	Program Name	Program Description	Funding Partner (* Indicates a funding partner in CDC fiscal year)	Committed Award	Cash	Cumulative Funding (All Years)
6/27/2022	12/30/2026	Investigating Safety and Efficacy of L9LS Monoclonal Antibodies in Western Kenya	To investigate novel interventions such as monoclonal antibodies (MAbs) against malaria. An intervention that could prevent malaria in children for a full 12 months in settings of perennial malaria transmission, such as Kenya, holds potential to reduce malaria morbidity and mortality substantially in this population at risk for severe malaria and death.				\$4,946,789.00
				Gates Foundation			
6/1/2018	6/30/2026	Laboratory Surveillance for Pneumococcal Meningitis in India	To strengthen laboratory surveillance for pneumococcal meningitis and serotyping in India to understand the impact of a pneumococcal conjugate vaccine rollout.				\$1,031,740.00
				Gates Foundation			
10/29/2024	3/31/2025	Literature Review of Pneumococcal Conjugate Vaccines	To support a literature review of pneumococcal conjugate vaccines (PCV) dosing schedules and impact assessments to guide discussions about potential changes to current guidance on PCV schedules, an analysis needed to support the WHO Strategic Advisory Group of Experts on Immunization (SAGE) PCV Working Group.				\$141,786.00
				World Health Organization (WHO)*	\$141,786.00		
2/20/2023	10/31/2025	Measles-Rubella Microarray Patch Evaluation	To evaluate the safety, tolerability and immunogenicity of a Measles-Rubella Microarray Patch (MR-MAP).				\$473,867.00
				PATH			
3/5/2020	2/28/2025	Mechanisms of Norovirus Protective Immunity	To screen a subset of human and mouse monoclonal antibodies for their ability to neutralize GI.1, a time ordered panel of GII.4 and GII.3 noroviruses using a novel human intestinal enteroid cell culture system.				\$407,840.00
				University of North Carolina at Chapel Hill			
9/1/2024	9/30/2026	Media Education Training Program	To support two annual two-day conferences for journalists from media outlets reaching rural, frontier and urban populations to provide training on where to access reliable health information.				\$160,000.00
				Alfred P. Sloan Foundation*	\$160,000.00		
6/6/2024	3/31/2026	MenAfriNet Meningitis Surveillance in Africa (MenAfriNet III)	To continue improving scientific understanding of meningitis to guide research on new vaccines and strategies and to optimize impact of existing vaccines in the African meningitis belt.				\$690,000.00
				Gates Foundation			
4/7/2020	11/7/2024	Monitoring Health Outcomes of Assisted Reproductive Technology	To provide research support for analysis of outcomes of assisted reproductive technologies.				\$662,072.00
				Open Philanthropy Project Fund			
6/1/2019	9/30/2025	Monitoring Malaria Treatment in the United States	To collect, manage and analyze data on the safety and efficacy of tafenoquine (Krintafel) used for anti-relapse therapy of malaria in the United States.				\$139,299.00
				GlaxoSmithKline Biologicals S.A.			
10/28/2019	12/6/2024	Multi-Center Zoliflodacin Study	To evaluate the efficacy of a single oral dose of zoliflodacin in treatment of patients with uncomplicated gonorrhea.				\$846,434.63
				Global Antibiotic Research & Development Partnership (GARDP Foundation)			
10/30/2024	3/31/2027	Multiplex Bead Assay Regional Hub for Nigeria and West Africa	To facilitate efficient and sustainable integrated disease surveillance within Nigeria and the West African sub-region through a Multiplex Bead Assay (MBA) Serosurveillance Regional Hub Project and South-to-South Technology Transfer.				\$800,000.00
				Gates Foundation*	\$800,000.00		
1/15/2024	3/15/2026	National Action Plan for Health Security Toolkit Benchmarks	To continue to increase health security in countries by improving their capacity and expanding support using new and more relevant tools of the National Action Plan for Health Security Toolkit in at least six countries.				\$499,992.21
				Resolve to Save Lives, Inc.			
8/1/2018	10/31/2024	Newborn Screening of Spinal Muscular Atrophy	To expedite the implementation of newborn screening for spinal muscular atrophy to prevent childhood death and disability.				\$1,500,000.00

Start Date	End Date	Program Name	Program Description	Funding Partner (* Indicates a funding partner in CDC fiscal year)	Committed Award	Cash	Cumulative Funding (All Years)
				Biogen MA, Inc.			
7/1/2022	11/30/2025	Next Generation Multipurpose Intravaginal Ring Technology	To evaluate the safety, pharmacokinetics and efficacy of Continuous Liquid Interface Production 3D printed intravaginal rings loaded with antiretroviral Islatravir.				\$272,150.00
				University of North Carolina at Chapel Hill			
7/12/2024	9/30/2027	Onsite Technical Support to Countries Conducting various Rotavirus Studies	To provide travel support for onsite technical assistance to countries conducting various rotavirus studies.				\$357,133.00
				Gates Foundation			
11/23/2015	5/31/2026	Opt-Out Chlamydia Screening Effectiveness	To explore the effectiveness of opt-out chlamydia screening via electronic health record prompt and to increase the percentage of women under the age of 25 who are screened for chlamydia at clinical encounters.				\$709,002.00
				Hologic, Inc.			
9/1/2021	8/31/2025	Origin of Innate Immunity Suppression	To further research how viral ovarian tumor protease (vOTU) activity is critical for replication and host tropism of nairoviruses.				\$470,834.65
				University of California, Riverside			
7/20/2022	6/30/2026	Pathogenic Paramyxovirus Replication in BioSafety Level 4 Lab (BSL-4) Containment	To develop cell culture and small animal models of Nipah virus replication and pathogenesis in a biosafety level (BSL) 4 lab.				\$2,791,302.00
				Gates Foundation			
4/5/2019	5/31/2027	Pneumococcal Conjugate Vaccine Surveillance and Evaluation in Burkina Faso	To support the introduction of a change in Burkina Faso's infant pneumococcal vaccine schedule to include a booster dose and to evaluate the impact of the country's capacity to control pneumococcal disease among children and adults.				\$3,824,907.00
				Gates Foundation			
11/1/2022	10/31/2026	Population-Level Analysis and Community Estimates (PLACES): Local Data for Better Health	To produce and disseminate high-quality, small-area health estimates that compose the Population-Level Analysis and Community Estimates (PLACES) public health data resource.				\$2,962,568.00
				Robert Wood Johnson Foundation*	\$1,562,868.00		
11/15/2024	10/31/2027	Respiratory Syncytial Virus (RSV) Sentinel Surveillance	To support the generation of Respiratory syncytial virus (RSV) burden data to inform country decision-making on RSV vaccine adoption in priority low and middle income countries.				\$3,299,943.00
				Gates Foundation*	\$3,299,943.00		
10/26/2023	6/30/2028	Rotavirus Vaccine effectiveness and safety in Nigeria	To support vaccine impact, effectiveness, and safety studies of Rotavac, an Indian-manufactured vaccine, that will be introduced and rolled out across all regions of Nigeria.				\$1,966,885.00
				Gates Foundation			
9/17/2023	8/31/2027	Rotavirus Vaccine Effectiveness in Indonesia	To support vaccine impact, effectiveness, and safety studies of rotavirus vaccine introduced and rolled out across all regions of Indonesia.				\$3,035,396.00
				Gates Foundation			
4/1/2022	12/31/2025	Rotavirus Vaccine Impact and Effectiveness Assessments	To ensure impact and effectiveness of rotavirus vaccines and sustain vaccine use by policy makers, physicians and parents to increase the speed of adoption of vaccine by other countries in Africa and around the world.				\$745,009.00
				Gavi Alliance			
10/1/2022	6/30/2025	Safety and Pharmacokinetics of Hydrogel Implants	To assess in vivo safety and pharmacokinetics of cabotegravir/levonorgestrel (CAB/LNG) hydrogel implants.				\$203,196.00
				Old Dominion University*	\$111,063.00		
4/3/2015	7/31/2025	Sickle Cell Data Collection	To build the framework for collecting data about individuals in the United States with sickle cell disease in order to monitor their health outcomes, evaluate current systems of care and inform the development of a comprehensive care model to meet the needs of these individuals throughout their life.				\$3,872,636.00
				Biogen MA, Inc.			
				Bioverativ, Inc.			
				Doris Duke Charitable Foundation, Inc.			

Start Date	End Date	Program Name	Program Description	Funding Partner (* Indicates a funding partner in CDC fiscal year)	Committed Award	Cash	Cumulative Funding (All Years)
				Global Blood Therapeutics, Inc.			
				Gods Garden			
				Novartis US Foundation			
				Pfizer, Inc.			
				Sanofi Genzyme			
				Vertex Pharmaceuticals Incorporated			
8/27/2022	7/31/2026	Support for Inactivated Rotavirus Vaccine	To support chemistry, manufacturing and control (CMC) and preclinical development of an inactivated rotavirus vaccine.				\$1,277,615.00
				Gates Foundation			
12/1/2021	12/31/2025	Technical Assistance for Pneumococcal Carriage Study Burkina Faso	To assess the impact of the Pneumococcal conjugate vaccine catch up campaign among internally displaced populations in the northern Sahel region of Burkina Faso. This effort will implement and evaluate the impact of changing the pneumococcal conjugate vaccine schedule.				\$347,348.00
				Davycas International			
12/7/2009	On-going	Together for Girls	To enable CDC to work with individual countries and regions to quantify the problem of sexual violence against girls and subsequently develop evidence-based policies and programs to protect children and prevent violence.				\$1,826,783.80
				Becton, Dickinson and Company (BD)			
				Henry Schein Cares Foundation			
				Nduna Foundation			
				United Nations Development Programme			
				Various Individual Contributors			